Cystatin C as a marker of residual renal function during continuous hemodiafiltration

被引:14
作者
Balík, M
Jabor, A
Waldauf, P
Kolár, M
Pavlisová, M
Brest'an, D
Hendl, J
Rychlík, I
机构
[1] Univ Hosp Kralovske Vinohrady, Dept Anaesthesia & Intens Care, CZ-10034 Prague 10, Czech Republic
[2] Dist Hosp Kladno, Dept Clin Biochem & Hematol, Kladno, Czech Republic
[3] Charles Univ Prague, Dept Kinanthropol, CR-11636 Prague 1, Czech Republic
[4] Univ Hosp Kralovske Vinohrady, Dept Med 2, Prague, Czech Republic
关键词
renal function; cystatin C; acute renal failure; renal replacement therapy; hemodiafiltration; glomerular filtration;
D O I
10.1159/000080936
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background: The level of residual renal function (RRF) has an important impact on follow-up in critically ill patients with renal failure. There is currently no clear marker of RRF. Methods: Cystatin C (cysC) concentrations were measured before and during the first 48 h of CVVHDF in 33 mechanically ventilated patients suffering from renal failure. Samples were drawn both from the ports proximal and distal to the filter. Each of the two control groups consisted of 10 patients. Results: The levels of cysC were significantly higher in the group where diuresis (Vu) remained low or decreased after 48 h of treatment (n = 21, Vu median 380 (80-935) ml/24 h, cysC range 4.44-3.42 mg/l) than in the group where Vu increased to the level of 1.5 ml.kg(-1).h(-1) or higher after 48 h of treatment (n = 12, Vu 4,570 (4,000-5,130) ml/24 h, cysC 3.17-2.46 mg/l, p < 0.01). Creatinine clearance taken before treatment was not different between the groups. Significant correlation between cysC levels and Vu was found (r = -0.44, p < 0.0001). CysC levels were significantly higher in non-survivors than in survivors (3.54 +/- 1.38 vs. 3.07 +/- 1.24, p < 0.03). Conclusion: The levels of cysC are inversely related to Vu. High levels of cysC are associated with low residual diuresis, longer duration of CVVHDF and higher intensive care unit mortality in patients treated with CVVHDF. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 28 条
[1]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[2]  
BRENNER BM, 1998, HARRISONS PRINCIPLES, P1498
[3]  
CHASSE R, 1994, PHARM APPROACH CRITI, P632
[4]   Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients [J].
Cimerman, N ;
Brguljan, PM ;
Krasovec, M ;
Suskovic, S ;
Kos, J .
CLINICA CHIMICA ACTA, 2000, 300 (1-2) :83-95
[5]  
Clark WR, 1998, KIDNEY INT, V53, pS133
[6]  
COHEN AJ, 1999, INTENS CARE MED, P911
[7]   Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment [J].
Coll, E ;
Botey, A ;
Alvarez, L ;
Poch, E ;
Quintó, L ;
Saurina, A ;
Vera, M ;
Piera, C ;
Darnell, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (01) :29-34
[8]   Intermittent versus continuous renal replacement therapy for acute renal failure in intensive care units:: results from a multicenter prospective epidemiological survey [J].
Guérin, C ;
Girard, R ;
Selli, JM ;
Ayzac, L .
INTENSIVE CARE MEDICINE, 2002, 28 (10) :1411-1418
[9]   THE APACHE-III PROGNOSTIC SYSTEM - RISK PREDICTION OF HOSPITAL MORTALITY FOR CRITICALLY ILL HOSPITALIZED ADULTS [J].
KNAUS, WA ;
WAGNER, DP ;
DRAPER, EA ;
ZIMMERMAN, JE ;
BERGNER, M ;
BASTOS, PG ;
SIRIO, CA ;
MURPHY, DJ ;
LOTRING, T ;
DAMIANO, A ;
HARRELL, FE .
CHEST, 1991, 100 (06) :1619-1636
[10]  
Kos J, 1998, CLIN CHEM, V44, P2556